X-Nico

unusual facts about fusion protein



Aflibercept

Aflibercept (INN, USAN) is a fusion protein approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap.

Behavioral neuroscience

Synapto-pHluorin is a technique that relies on a fusion protein that combines a synaptic vesicle membrane protein and a pH sensitive fluorescent protein.

Hypereosinophilic syndrome

A proportion of patients have a mutation involving the PDGFRA and FIP1L1 genes on the fourth chromosome, leading to a tyrosine kinase fusion protein.


see also

Alveolar rhabdomyosarcoma

It can be associated with a fusion protein between PAX3 and FKHR (now known as FOXO1).

Edward Tobinick

Tobinick has been issued patents for methods of perispinal administration, of certain recombinant DNA-derived (biologic) therapeutics including the TNF receptor fusion protein etanercept, for the treatment of certain neurologic disorders with widespread unmet medical need, including Alzheimer's disease; pain due to cancer metastasis to bone; severe, intractable, intervertebral disc-related pain and radiculopathy (including sciatica); and myasthenia gravis.

Tpr-met fusion protein

Tpr-met fusion protein is an oncogene fusion protein consisting of TPR and MET.